Emcure Pharmaceuticals (NSE:EMCURE) Beneish M-Score: -2.16 (As of Jun. 27, 2026)


NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,880.20
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Beneish M-Score?

Emcure Pharmaceuticals NSE:EMCURE +2.18% 41 Beneish M-Score is -2.16 as of Jun. 27, 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Emcure Pharmaceuticals ranks worse than 72.34% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.16 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Emcure Pharmaceuticals's Beneish M-Score or its related term are showing as below:

NSE:EMCURE' s Beneish M-Score Range Over the Past 10 Years
Min: -2.49   Med: -2.42   Max: -2.16
Current: -2.16

During the past 6 years, the highest Beneish M-Score of Emcure Pharmaceuticals was -2.16. The lowest was -2.49. And the median was -2.42.


Emcure Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Beneish M-Score Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial 0.00 -2.44 -2.49 -2.40 -2.16

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 0.00 0.00 0.00 -2.16

NSE:EMCURE vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emcure Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Emcure Pharmaceuticals's Beneish M-Score falls into.


NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Emcure Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0696+0.528 * 0.9981+0.404 * 1.0487+0.892 * 1.1656+0.115 * 0.951
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.001996-0.327 * 1.2169
=-2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹25,627 Mil.
Revenue was ₹92,035 Mil.
Gross Profit was ₹55,465 Mil.
Total Current Assets was ₹56,121 Mil.
Total Assets was ₹96,125 Mil.
Property, Plant and Equipment(Net PPE) was ₹24,908 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹4,150 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹39,122 Mil.
Long-Term Debt & Capital Lease Obligation was ₹5,145 Mil.
Net Income was ₹9,244 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹9,435 Mil.
Total Receivables was ₹20,554 Mil.
Revenue was ₹78,960 Mil.
Gross Profit was ₹47,494 Mil.
Total Current Assets was ₹45,559 Mil.
Total Assets was ₹82,327 Mil.
Property, Plant and Equipment(Net PPE) was ₹24,440 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹3,842 Mil.
Selling, General, & Admin. Expense(SGA) was ₹8,376 Mil.
Total Current Liabilities was ₹26,683 Mil.
Long-Term Debt & Capital Lease Obligation was ₹4,473 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(25626.64 / 92035.4) / (20554.4 / 78959.97)
=0.278443 / 0.260314
=1.0696

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(47493.94 / 78959.97) / (55464.78 / 92035.4)
=0.601494 / 0.602646
=0.9981

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (56121.03 + 24908.22) / 96124.81) / (1 - (45558.64 + 24440.46) / 82327.23)
=0.157041 / 0.149745
=1.0487

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=92035.4 / 78959.97
=1.1656

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3841.78 / (3841.78 + 24440.46)) / (4150.46 / (4150.46 + 24908.22))
=0.135837 / 0.14283
=0.951

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 92035.4) / (8376.32 / 78959.97)
=0 / 0.106083
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5144.91 + 39122.41) / 96124.81) / ((4472.54 + 26682.71) / 82327.23)
=0.460519 / 0.378432
=1.2169

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9243.61 - 0 - 9435.45) / 96124.81
=-0.001996

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Emcure Pharmaceuticals has a M-score of -2.16 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.16 mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Beneish M-Score of -2.16 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Emcure Pharmaceuticals and its competitors. According to the industry distribution chart, Emcure Pharmaceuticals ranks #659 out of 911 companies in the Drug Manufacturers industry, placing it in the top 72.3%.
Is Emcure Pharmaceuticals' Beneish M-Score too high?
Emcure Pharmaceuticals' current Beneish M-Score is -2.16. Based on the distribution chart, Emcure Pharmaceuticals ranks #659 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #659 out of 911 companies for Beneish M-Score. This places Emcure Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Beneish M-Score is -2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Beneish M-Score of -2.16. The current Beneish M-Score is -2.16. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Beneish M-Score is -2.16 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,880.20
Price